RT Journal Article
SR Electronic
T1 COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.12.21257125
DO 10.1101/2021.05.12.21257125
A1 Danielle T. Hunt
A1 Jennifer L. Yates
A1 Karen E. Kulas
A1 Kyle Carson
A1 Theresa Lamson
A1 Valerie Demarest
A1 Andrea Furuya
A1 Kelly Howard
A1 Mary Marchewka
A1 Randy Stone
A1 Heidi Tucker
A1 Casey Warszycki
A1 Jim Yee
A1 He S. Yang
A1 Sabrina Racine-Brzostek
A1 Zhen Zhao
A1 Monir Ejemel
A1 Qi Li
A1 Yang Wang
A1 Sebastian Fernando
A1 Francesca La Carpia
A1 Eldad A. Hod
A1 Kathleen A. McDonough
A1 William T. Lee
YR 2021
UL http://medrxiv.org/content/early/2021/05/15/2021.05.12.21257125.abstract
AB The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of new molecular and serological tests. Here, we describe a multiplexed serological assay developed as the global pandemic moved into New York State in the spring of 2020. The original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-2 protein antigens (nucleocapsid, spike and spike domains, spike and nucleocapsid proteins from seasonal human coronaviruses). Besides being highly versatile due to multiplex capabilities, the assay was highly specific and sensitive and adaptable to measuring both total antibodies and antibody isotypes. While determining the assay performance characteristics, we were able to identify antibody production patterns (e.g., kinetics of isotypes, individual variations) for total antibodies and individual antibody classes. Overall, the results provide insights into the laboratory response to new serology needs, and how the evolution and fine-tuning of a serology assay helped contribute to a better understanding of the antibody response to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was performed in part under a Project Award Agreement from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance award 70NANB20H037 from the U.S. Department of Commerce, National Institute of Standards and Technology. Additional support was provided by a grant (P20-000271) from the New York Community Trust. A portion of the work described in this publication was supported by Cooperative Agreement Number NU50CK000516 from the Centers of Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All testing and archiving of human specimens were done under a declared New York State Public Health Emergency and also approved by New York State Department of Health Institutional Review Board (IRB 20-021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this submitted article (and its supplementary information files)1AbbreviationsCOVID-19coronavirus disease 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2HuCOVhuman endemic (seasonal) coronavirusesAbantibodyDILDiagnostic Immunology Laboratory at the Wadsworth CenterNnucleocapsid proteinRBDreceptor-binding domainMFImedian fluorescent intensityFDAFood and Drug AdministrationEUAEmergency Use AuthorizationMIAmicrosphere immunoassay